Logo image of LVTX

LAVA THERAPEUTICS NV (LVTX) Stock Fundamental Analysis

NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD

0.9575  +0.02 (+2.41%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LVTX. LVTX was compared to 571 industry peers in the Biotechnology industry. LVTX may be in some trouble as it scores bad on both profitability and health. LVTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LVTX had negative earnings in the past year.
In the past year LVTX has reported a negative cash flow from operations.
In the past 5 years LVTX always reported negative net income.
In the past 5 years LVTX reported 4 times negative operating cash flow.
LVTX Yearly Net Income VS EBIT VS OCF VS FCFLVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -33.16%, LVTX is in the better half of the industry, outperforming 63.81% of the companies in the same industry.
LVTX has a Return On Equity (-83.78%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.16%
ROE -83.78%
ROIC N/A
ROA(3y)-32.03%
ROA(5y)-56.37%
ROE(3y)-52.47%
ROE(5y)-105.71%
ROIC(3y)N/A
ROIC(5y)N/A
LVTX Yearly ROA, ROE, ROICLVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

LVTX's Gross Margin of 97.90% is amongst the best of the industry. LVTX outperforms 97.33% of its industry peers.
The Profit Margin and Operating Margin are not available for LVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LVTX Yearly Profit, Operating, Gross MarginsLVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

LVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LVTX has about the same amount of shares outstanding.
LVTX has a worse debt/assets ratio than last year.
LVTX Yearly Shares OutstandingLVTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
LVTX Yearly Total Debt VS Total AssetsLVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of -2.36, we must say that LVTX is in the distress zone and has some risk of bankruptcy.
LVTX's Altman-Z score of -2.36 is in line compared to the rest of the industry. LVTX outperforms 50.80% of its industry peers.
LVTX has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LVTX (0.18) is worse than 70.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -2.36
ROIC/WACCN/A
WACC7.37%
LVTX Yearly LT Debt VS Equity VS FCFLVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

LVTX has a Current Ratio of 5.36. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.36, LVTX is in line with its industry, outperforming 56.51% of the companies in the same industry.
LVTX has a Quick Ratio of 5.36. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LVTX (5.36) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.36
Quick Ratio 5.36
LVTX Yearly Current Assets VS Current LiabilitesLVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.35% over the past year.
The Revenue for LVTX has decreased by -18.87% in the past year. This is quite bad
LVTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.59% yearly.
EPS 1Y (TTM)46.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
Revenue 1Y (TTM)-18.87%
Revenue growth 3Y24.59%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 10.04% on average over the next years. This is quite good.
LVTX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.71% yearly.
EPS Next Y26.55%
EPS Next 2Y6.41%
EPS Next 3Y9.99%
EPS Next 5Y10.04%
Revenue Next Year-38.83%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-2.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LVTX Yearly Revenue VS EstimatesLVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
LVTX Yearly EPS VS EstimatesLVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LVTX Price Earnings VS Forward Price EarningsLVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LVTX Per share dataLVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.41%
EPS Next 3Y9.99%

More info and screens

0

5. Dividend

5.1 Amount

LVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LAVA THERAPEUTICS NV

NASDAQ:LVTX (2/21/2025, 8:00:00 PM)

0.9575

+0.02 (+2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-10 2024-12-10/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners35.48%
Inst Owner Change-98.2%
Ins Owners0.52%
Ins Owner Change0%
Market Cap25.17M
Analysts80
Price Target2.38 (148.56%)
Short Float %0.16%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.54%
Min EPS beat(2)-36.66%
Max EPS beat(2)15.58%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-88.24%
Max EPS beat(4)84.31%
EPS beat(8)6
Avg EPS beat(8)2.43%
EPS beat(12)10
Avg EPS beat(12)21.82%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-67.82%
EPS NQ rev (1m)-1.72%
EPS NQ rev (3m)28.05%
EPS NY rev (1m)5.37%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)121.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.43
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.28
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.16%
ROE -83.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.9%
FCFM N/A
ROA(3y)-32.03%
ROA(5y)-56.37%
ROE(3y)-52.47%
ROE(5y)-105.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.21%
Cap/Sales 0.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.36
Quick Ratio 5.36
Altman-Z -2.36
F-Score5
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)89.49%
Cap/Depr(5y)133.9%
Cap/Sales(3y)9.68%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.29%
EPS Next Y26.55%
EPS Next 2Y6.41%
EPS Next 3Y9.99%
EPS Next 5Y10.04%
Revenue 1Y (TTM)-18.87%
Revenue growth 3Y24.59%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-38.83%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-2.71%
EBIT growth 1Y43.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1250.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1064.65%
OCF growth 3YN/A
OCF growth 5YN/A